A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma
机构：[1]State Key Laboratory of Biotherapy and Cancer, Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, PR China四川大学华西医院[2]Core Laboratory, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospitals, Chengdu, PR China四川省人民医院[3]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, PR China[4]Department of Oncology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospitals, Chengdu, PR China四川省人民医院[5]Chengdu Cancer Bioengineering Research Institute, Chengdu, PR China
Context: We previously reported a novel tumour associated antigen (TTA) with molecular weight around 48 kDa and identified the novel TTA as a fragment derived from human DNA-topoiomerase I (TOP1). We termed the novel TAA as TOPO48 and termed autoantibody against the TAA as anti-TOPO48 autoantibody. Objective: To explore the clinical significance of anti-TOPO48 autoantibody in patients with colorectal carcinoma (CRC). Materials and methods: Serum levels of the autoantibody in patients with CRC or benign tumours and healthy volunteers were measured with a specific ELISA. Results: CRC patients at early stage had higher frequency of positive levels of the autoantibody and CRC patients with positive autoantibody levels had higher overall survival rate than those with negative autoantibody levels. Conclusion: The autoantibody is a potential biomarker for early diagnosis and favourable prognosis of CRC.
基金：
Research and Development Programme of the Chengdu Technology Bureau [KJXM20030826]
第一作者机构：[1]State Key Laboratory of Biotherapy and Cancer, Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, PR China
共同第一作者：
通讯作者：
通讯机构：[1]State Key Laboratory of Biotherapy and Cancer, Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, PR China[3]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu, PR China[*1]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Chengdu,Sichuan, PR China[*2]Chengdu Cancer Bioengineering Research Institute, Chengdu, Sichuan, PR China
推荐引用方式(GB/T 7714)：
Zhao Feng,Cao Mei,Jiang Xiao-Hui,et al.A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma[J].BIOMARKERS.2020,25(2):149-156.doi:10.1080/1354750X.2020.1714734.
APA：
Zhao, Feng,Cao, Mei,Jiang, Xiao-Hui,Xie, Ke,Ye, Shang-Rong&Yie, Shang-Mian.(2020).A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma.BIOMARKERS,25,(2)
MLA：
Zhao, Feng,et al."A specific autoantibody against a novel tumour-association antigen derived from human DNA-topoiomerase I is a potential biomarker for early diagnosis and favourable prognosis in patients with colorectal carcinoma".BIOMARKERS 25..2(2020):149-156
